Estados Unidos · Plataformas y datos · Morningstar

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Publicado por Morningstar · Estados Unidos hace 14 h

Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

También te puede interesar

Advanced Micro Devices, Inc. $AMD Stake Lessened by Atlatl Advisers LLC

The Next AI Infrastructure Winner Isn't a Memory Stock. It's This.

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

3 UK Consumer Staples Shares Investors May Watch As Confidence Slumps

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Hooters closes 35-year-old location after shutting 55 restaurants

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Compartir

También te puede interesar

Advanced Micro Devices, Inc. $AMD Stake Lessened by Atlatl Advisers LLC

The Next AI Infrastructure Winner Isn't a Memory Stock. It's This.

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

3 UK Consumer Staples Shares Investors May Watch As Confidence Slumps

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

Hooters closes 35-year-old location after shutting 55 restaurants